Indoco Remedies Ltd. — Major Shareholding Notification 2021

Apr 6, 2021

April 1, 2021

The Listing Department	The Listing Department
National Stock Exchange of India Ltd.	The Bombay Stock Exchange Ltd.
Exchange Plaza,	25thFloor, P J Towers
Bandra – Kurla Complex	Dalal Street
Bandra (East)	Fort
Mumbai–400 051	Mumbai 400001

Sub; Disclosure under Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Dear Sir

Please find herewith the Statement in the prescribed format under Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011, showing the names, number of shares and percentage of shares or voting rights of promoter, members of the promoter group and PAC with him as on 31[st] March, 2021.

I am authorized to sign and submit the Disclosure under Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011 on behalf of the persons detailed in the statement.

Kindly take the above on record and acknowledge receipt

Thanking You

Yours faithfully

==> picture [94 x 29] intentionally omitted <==

Suresh G Kare

Cc: The Company Secretary Indoco Remedies Limited Indoco House, 166 CST Road Kalina Santacruz (E) Mumbai 400098

Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011

Part‐A‐ Details of Shareholding

1. Name of the Target Company (TC)	INDOCO REMEDIES LIMITED	INDOCO REMEDIES LIMITED	INDOCO REMEDIES LIMITED
2. Name(s) of the stock exchange(s) where the shares of the TC are listed	The Bombay Stock Exchange / The National Stock Exchange
3. Particulars of the shareholder(s) : a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants convertible securities and any other instrument that would entitle the securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.
b. Name(s) of promoter(s), members of the promoter group and PAC with him.	1. Mr. Suresh G Kare 2. Mrs. Aruna S Kare 3. Mrs. Aditi M Panandikar 4. Mrs. Madhura Ramani 5. Shanteri Investment Pvt Ltd 6. SPA Holdings Pvt. Ltd. 7. Suresh G Kare (HUF) 8. Suresh Govind KAre (HUF) 9. Mrs. Sharada R. Kare 10. Mrs. Pratima A Vaidya 11. Mrs. Sudha M Pai 12. Mr. Megh M Panandikar 13. Ms. Mahika M Panandikar 14. Mr. Rohan A Ramani 15. Mr. Ramanth G Kare
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share capital	% of total diluted share capital of TC share capital of TC(*)
As of March 31st of the year, holding of: a) shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e)Anyother instrument that would entitle the holder to receive shares in the TC	54081146 NA NA NA NA	58.69% NA NA NA NA	NA NA NA NA NA
Total	54081146	58.69%

==> picture [94 x 27] intentionally omitted <==

Part‐B**

Name of the Target Company:	Indoco Remedies Limited	Indoco Remedies Limited
Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/P romoter Group	PAN of the person and PAC's
1. Mr. Suresh G Kare	Promoter
2. Mrs. Aruna S Kare	Promoter
3. Mrs. Aditi M Panandikar	Promoter
4. Mrs. Madhura A. Ramani	Promoter
5. Shanteri Investment Pvt Ltd	Promoter
6. Suresh Govind Kare(HUF)	Promoter
7. SPA Holdings Pvt. Ltd.	PAC
8. Mr. Milind S. Panandikar	PAC
9. Mrs. Sharada R. Kare	PAC
10. Ms Sudha M Pai	PAC
11. Mr. Pratima A Vaidya	PAC
12. Mr. Megh M Panandikar	PAC
13. Ms. Mahika M Panandikar	PAC
14. Mr. Rohan A Ramani	PAC
15. Mr. Ramnath G Kare	PAC

==> picture [94 x 27] intentionally omitted <==

Signature of the Authorised Signatory

Place: Mumbai

Date: 1st April, 2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part‐B shall be disclosed to the Stock Exchanges but shall not be disseminated.